Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review

•Positive serological test results have marked heterogeneity of sensitivity.•Diagnosis of coronavirus disease 2019 with either IgM+ or IgG+ has favourable diagnostic accuracy.•The sensitivity of antibody testing might be improved by testing 2 weeks after symptom onset.•IgA might be a surrogate provi...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of infectious diseases Vol. 104; pp. 415 - 422
Main Authors Chen, Mengyu, Qin, Rundong, Jiang, Mei, Yang, Zhaowei, Wen, Weiping, Li, Jing
Format Journal Article
LanguageEnglish
Published Canada Elsevier Ltd 01.03.2021
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases
Elsevier
Subjects
Online AccessGet full text
ISSN1201-9712
1878-3511
1878-3511
DOI10.1016/j.ijid.2021.01.016

Cover

Loading…
More Information
Summary:•Positive serological test results have marked heterogeneity of sensitivity.•Diagnosis of coronavirus disease 2019 with either IgM+ or IgG+ has favourable diagnostic accuracy.•The sensitivity of antibody testing might be improved by testing 2 weeks after symptom onset.•IgA might be a surrogate providing better diagnostic accuracy compared with IgG or IgM. The coronavirus disease 2019 (COVID-19) pandemic has had a devastating impact worldwide, and timely detection and quarantine of infected patients are critical to prevent spread of disease. Serological antibody testing is an important diagnostic method used increasingly in clinics, although its clinical application is still under investigation. A meta-analysis was conducted to compare the diagnostic performance of severe acute respiratory syndrome coronavirus-2 antibody tests in patients with COVID-19. The test results analysed included: (1) IgM-positive but IgG-negative (IgM+IgG−); (2) IgG-positive but IgM-negative (IgG+IgM−); (3) both IgM-positive and IgG-positive (IgM+IgG+); (4) IgM-positive without IgG information (IgM+IgG+/−); (5) IgG-positive without IgM information (IgG+IgM+/−); (6) either IgM-positive or IgG-positive (IgM+ or IgG+); and (7) IgA-positive (IgA+). Sixty-eight studies were included. Pooled sensitivities for IgM+IgG−, IgG+IgM−, IgM+IgG+, IgM+IgG+/−, IgG+IgM+/−, and IgM+ or IgG+ were 6%, 7%, 53%, 68%, 73% and 79% respectively. Pooled specificities ranged from 98% to 100%. IgA+ had a pooled sensitivity of 78% but a relatively low specificity of 88%. Tests conducted 2 weeks after symptom onset showed better diagnostic accuracy than tests conducted earlier. Chemiluminescence immunoassay and detection of S protein as the antigen could offer more accurate diagnostic results. These findings support the supplemental role of serological antibody tests in the diagnosis of COVID-19. However, their capacity to diagnose COVID-19 early in the disease course could be limited.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
These authors contributed equally to this paper.
ISSN:1201-9712
1878-3511
1878-3511
DOI:10.1016/j.ijid.2021.01.016